Moleculin Biotech, Inc.
N/A
USD
N/A
N/A
...
Chart
Financials
Description
MBRX Company Description
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
MBRX Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view MBRX Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of MBRX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by MBRX's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of MBRX in WallStreetBets Daily Discussion
MBRX News
Recent insights relating to MBRX
CNBC Recommendations
Recent picks made for MBRX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in MBRX
Corporate Flights
Flights by private jets registered to MBRX
Our Analysis